美股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)

25.90

0.0000

成交量：- -

成交额：1.56万

市值：29.17亿

市盈率：-12.83

高：25.90

开：25.90

低：25.90

收：25.90

52周最高：29.99

52周最低：5.45

股本：1.13亿

流通股本：1.13亿

量比：- -

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-2.0190

净资产收益率：--

总资产收益率：--

市净率：--

市盈率(LYR):- -

数据加载中...

总览公司新闻资讯公告

公司资料

公司名字：

NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)

交易所：

NASDAQ

成立时间：

- -

员工人数：

- -

公司地址：

- -

官网：

http://www.newamsterdampharma.com

邮编：

- -

电话：

- -

传真：

- -

简介：

NewAmsterdam Pharma Company N.V.于2019年10月17日以NewAmsterdam Pharma B.V.的名义根据荷兰法律成立为一家私人有限责任公司。NewAmsterdam Pharma于2021年10月更名为NewAmsterdam Pharma Holding B.V.。他们是一家临床阶段的生物制药公司，为心血管疾病（CVD）高危患者开发口服非他汀类药物，这些患者的低密度脂蛋白胆固醇（LDL-C或LDL）残留升高，而现有疗法对这些患者不够有效或耐受良好。作为他汀类药物的辅助药物，一种有效的、具有成本效益的和方便的低密度脂蛋白降低疗法存在着巨大的未满足需求。他汀类药物是目前高胆固醇高危CVD患者的标准护理。他们的主要候选产品obicetrapib是一种下一代口服低剂量胆固醇酯转移蛋白（CETP）抑制剂，目前正在进行四项3期和2b期临床试验，作为单一疗法和依折麦布联合疗法，用于降低LDL-C和预防主要心血管不良事件（“MACE”）。

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/NAMSW/company"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NAMSW","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","market":"US","secType":"STK","nameCN":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)","latestPrice":25.9,"timestamp":1771519934875,"preClose":25.9,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":112628458,"shares":112628458,"eps":-2.019,"marketStatus":"交易中","change":0,"latestTime":"02-19 11:52:14 EST","open":25.9,"high":25.9,"low":25.9,"amount":15629.09992,"amplitude":0,"askPrice":25.99,"askSize":100,"bidPrice":20.94,"bidSize":100,"shortable":3,"etf":0,"ttmEps":-2.019,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1771534800000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":25.9,"postHourTrading":{"tag":"盘后","latestPrice":25.9,"preClose":25.97,"latestTime":"16:00 EST","volume":1,"amount":25.9,"timestamp":1771448401123,"change":-0.07,"changeRate":-0.002695,"amplitude":0},"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NAMSW\",,,,,undefined,":{"symbol":"NAMSW","floatShares":112628458,"roa":"--","roe":"--","lyrEps":0,"shares":112628458,"dividePrice":0,"high":25.9,"amplitude":0,"preClose":25.9,"low":25.9,"week52Low":5.45,"pbRate":"--","week52High":29.99,"institutionHeld":0,"latestPrice":25.9,"eps":-2.019,"divideRate":0,"volume":0,"delay":0,"ttmEps":-2.019,"open":25.9,"prevYearClose":23,"prevWeekClose":23.18,"prevMonthClose":19.45,"prevQuarterClose":23,"fiveDayClose":22.5,"twentyDayClose":22,"sixtyDayClose":28.44},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NAMSW\",params:#limit:5,,,undefined,":[{"date":"2026-02-18","symbol":"NAMSW","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1771405200000,"name":null,"time":"盘前","dateTimestamp":1771390800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NAMSW\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NAMSW\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.newamsterdampharma.com","stockEarnings":[{"period":"1week","weight":0.1542},{"period":"1month","weight":0.2818},{"period":"3month","weight":-0.0868},{"period":"6month","weight":0.8713},{"period":"1year","weight":1.9082},{"period":"ytd","weight":0.1291}],"compareEarnings":[{"period":"1week","weight":-0.0082},{"period":"1month","weight":-0.0078},{"period":"3month","weight":0.0517},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1223},{"period":"ytd","weight":0.0064}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"NewAmsterdam Pharma Company N.V.于2019年10月17日以NewAmsterdam Pharma B.V.的名义根据荷兰法律成立为一家私人有限责任公司。NewAmsterdam Pharma于2021年10月更名为NewAmsterdam Pharma Holding B.V.。他们是一家临床阶段的生物制药公司，为心血管疾病（CVD）高危患者开发口服非他汀类药物，这些患者的低密度脂蛋白胆固醇（LDL-C或LDL）残留升高，而现有疗法对这些患者不够有效或耐受良好。作为他汀类药物的辅助药物，一种有效的、具有成本效益的和方便的低密度脂蛋白降低疗法存在着巨大的未满足需求。他汀类药物是目前高胆固醇高危CVD患者的标准护理。他们的主要候选产品obicetrapib是一种下一代口服低剂量胆固醇酯转移蛋白（CETP）抑制剂，目前正在进行四项3期和2b期临床试验，作为单一疗法和依折麦布联合疗法，用于降低LDL-C和预防主要心血管不良事件（“MACE”）。","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":0.536633},{"month":2,"riseRate":0.6,"avgChangeRate":0.089708},{"month":3,"riseRate":0.2,"avgChangeRate":-0.24039},{"month":4,"riseRate":0.8,"avgChangeRate":0.178974},{"month":5,"riseRate":0,"avgChangeRate":-0.269123},{"month":6,"riseRate":0.6,"avgChangeRate":-0.001234},{"month":7,"riseRate":0.4,"avgChangeRate":1.643099},{"month":8,"riseRate":0.6,"avgChangeRate":-0.000678},{"month":9,"riseRate":0.4,"avgChangeRate":0.030454},{"month":10,"riseRate":0.8,"avgChangeRate":0.20425},{"month":11,"riseRate":0.8,"avgChangeRate":0.092319},{"month":12,"riseRate":0.6,"avgChangeRate":0.101716}],"exchange":"NASDAQ","name":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)","nameEN":"NEWAMSTERDAM PHARMA CO NV C/WTS 22/11/2027 (TO PUR COM)"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"NAMSW\",market:\"US\",,,undefined,":null}}